person · Reporting owner

Germano Geno J

Disclosed activity across 8 companies

Tapewire entity: 16443
SEC CIK: 0001424383

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Entera Bio Ltd.ENTX · Entity 5464	Director	August 07, 2026	August 07, 2026
Harmony Biosciences Holdings, Inc.HRMY · Entity 4381	Director	May 14, 2026	May 19, 2026
PFIZER INCPFE · Entity 2863	Group President	February 25, 2015	February 27, 2015
PRECIGEN, INC.XON · Entity 4356	President	September 22, 2016	September 26, 2016
PRECISION BIOSCIENCES INCDTIL · Entity 6284	Director	September 25, 2026	September 29, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Entera Bio Ltd.

Report date August 07, 2026 · Filed August 07, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary Shares, par value NIS 0.0000769 per shareSEC Table I · non-derivative	Direct	65,014	Reported balance After 2026-08-07 transaction · row 1 1 source row Row 1 · 2026-08-07 · Grant · Acquired 25,014 · Balance 65,014 F1: The Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Person in lieu of the cash fees the Reporting Person was entitled to for services rendered as a director of the Company for the first quarter and second quarter of 2026. This grant of shares was approved by the Board on August 5, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares, which occurred on August 7, 2026.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.37 · Expires 2036-05-07	Direct	50,000	Reported balance After 2026-08-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-08-07 · Grant · Acquired 50,000 · Balance 50,000 F2: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on February 4, 2026, with one-third of the options vesting on February 4, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan (the "Plan")).
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.37 · Expires 2036-05-07	Direct	43,014	Reported balance After 2026-08-07 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-08-07 · Grant · Acquired 43,014 · Balance 43,014 F3: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest on a quarterly basis over a one-year period that began on February 4, 2026, subject to full acceleration upon a Change in Control (as defined in the Plan).

Filing footnotes · ownership attribution and instrument terms

F1: The Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Person in lieu of the cash fees the Reporting Person was entitled to for services rendered as a director of the Company for the first quarter and second quarter of 2026. This grant of shares was approved by the Board on August 5, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares, which occurred on August 7, 2026.

F2: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on February 4, 2026, with one-third of the options vesting on February 4, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan (the "Plan")).

F3: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest on a quarterly basis over a one-year period that began on February 4, 2026, subject to full acceleration upon a Change in Control (as defined in the Plan).

Harmony Biosciences Holdings, Inc.

Report date May 14, 2026 · Filed May 19, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $30.76 · Expires 2036-05-14	Direct	21,231	Reported balance After 2026-05-14 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-14 · Grant · Acquired 21,231 · Balance 21,231 F1: The stock option shall vest in 36 equal monthly installments beginning on June 14, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option shall vest in 36 equal monthly installments beginning on June 14, 2026.

PFIZER INC

Report date February 25, 2015 · Filed February 27, 2015

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	308,254	Ending reported balance After 2015-02-25 transaction · row 5 5 source rows · reconciled sequence Row 1 · 2015-02-25 · Exercise / conversion · Acquired 83,333 · Balance 354,531 F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Row 2 · 2015-02-25 · Grant · Acquired 17,893 · Balance 372,424 F2: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Row 3 · 2015-02-25 · Tax withholding · Disposed 6,474 · Balance 365,950 F3: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Row 4 · 2015-02-25 · Tax withholding · Disposed 24,856 · Balance 341,094 F4: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Row 5 · 2015-02-25 · Tax withholding · Disposed 32,840 · Balance 308,254 F5: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F6: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $17.69 · Expires 2015-02-25	Direct	0	Reported balance After 2015-02-25 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2015-02-25 · Exercise / conversion · Disposed 83,333 · Balance 0
Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $34.59 · Expires 2020-02-26	Direct	144,928	Reported balance After 2015-02-26 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2015-02-26 · Grant · Acquired 144,928 · Balance 144,928 F8: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.
Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $34.59 · Expires 2022-02-26	Direct	120,805	Reported balance After 2015-02-26 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2015-02-26 · Grant · Acquired 120,805 · Balance 120,805 F9: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.
Common StockSEC Table I · non-derivative	IndirectBy children	1,587	Reported balance Holding disclosure · report date 2015-02-25 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 1,587 F7: The reporting person disclaims beneficial ownership of shares held by members of his family.
Common StockSEC Table I · non-derivative	IndirectBy Rule 16b-3 Plan	1,161	Reported balance Holding disclosure · report date 2015-02-25 · row 7 Holding and transaction disclosures are not merged. 1 source row Row 7 · Balance 1,161

Filing footnotes · ownership attribution and instrument terms

F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

F2: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon).

F3: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon).

F4: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

F5: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F6: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

F7: The reporting person disclaims beneficial ownership of shares held by members of his family.

F8: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F9: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

PRECIGEN, INC.

Report date September 22, 2016 · Filed September 26, 2016

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Option to Purchase Common Stock (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.94 · Expires 2026-05-31	Direct	1,000,000	Reported balance After 2016-09-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2016-09-22 · Grant · Acquired 1,000,000 · Balance 1,000,000 F1: This award represents the Issuer's remaining obligation to grant the reporting person option awards for 2,000,000 shares. A Form 4 dated June 3, 2016 reported that the reporting person previously received an option for 2,000,000 shares. That Form 4 has subsequently been amended to reflect that the initial grant was only effective with respect to 1,000,000 shares. This Form 4 reports that the reporting person has now received an option for the remaining 1,000,000 shares. F2: These options vest in 25% increments on June 1, 2017, 2018, 2019 and 2020.

Filing footnotes · ownership attribution and instrument terms

F1: This award represents the Issuer's remaining obligation to grant the reporting person option awards for 2,000,000 shares. A Form 4 dated June 3, 2016 reported that the reporting person previously received an option for 2,000,000 shares. That Form 4 has subsequently been amended to reflect that the initial grant was only effective with respect to 1,000,000 shares. This Form 4 reports that the reporting person has now received an option for the remaining 1,000,000 shares.

F2: These options vest in 25% increments on June 1, 2017, 2018, 2019 and 2020.

PRECISION BIOSCIENCES INC

Report date September 25, 2026 · Filed September 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	47,492	Reported balance After 2026-09-25 transaction · row 1 1 source row Row 1 · 2026-09-25 · Purchase · Acquired 2,609 · Balance 47,492

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Bioverativ Inc.

Report date March 08, 2018 · Filed March 08, 2018

Section 16 reporting ended · disclosed 2018-03-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-03-08 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-03-08 · Disposition to issuer · Disposed 5,455 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock. F2: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes.
Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $55.04	Direct	0	Reported balance After 2018-03-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-03-08 · Disposition to issuer · Disposed 21,729 · Balance 0 F4: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock.

F2: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").

F3: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes.

F4: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.

MEDICINES CO /DE

Report date January 06, 2020 · Filed January 06, 2020

Section 16 reporting ended · disclosed 2020-01-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-01-06 transaction · row 1 1 source row Row 1 · 2020-01-06 · Disposition to issuer · Disposed 7,429 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of November 23, 2019 (the "Merger Agreement"), by and among the Company, Novartis AG ("Parent") and Medusa Merger Corporation ("Purchaser"), on January 6, 2020, Purchaser was merged with and into the Company (the "Merger"), with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each a "Share") was converted into the right to receive $85.00 per Share, net to the seller in cash (the "Offer Price"). F2: The number of Shares reported includes 3,663 unvested restricted Shares (each a "Restricted Share"). Each Restricted Share that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser automatically became fully vested as of immediately prior to, and contingent upon, the effective time of the Merger and was treated in the same manner as an outstanding Share.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $30.90	IndirectBy grantor retained annuity trust	Reported balance After 2020-01-06 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-01-06 · Disposition to issuer · Disposed 27,243 · Balance 0 F3: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option. F4: In August 2019, the Reporting Person contributed the Options to a grantor retained annuity trust with his children as beneficiaries.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $33.86	IndirectBy grantor retained annuity trust	Reported balance After 2020-01-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-01-06 · Disposition to issuer · Disposed 9,141 · Balance 0 F3: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option. F4: In August 2019, the Reporting Person contributed the Options to a grantor retained annuity trust with his children as beneficiaries.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $34.81	IndirectBy grantor retained annuity trust	Reported balance After 2020-01-06 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-01-06 · Disposition to issuer · Disposed 8,410 · Balance 0 F3: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option. F4: In August 2019, the Reporting Person contributed the Options to a grantor retained annuity trust with his children as beneficiaries.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of November 23, 2019 (the "Merger Agreement"), by and among the Company, Novartis AG ("Parent") and Medusa Merger Corporation ("Purchaser"), on January 6, 2020, Purchaser was merged with and into the Company (the "Merger"), with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each a "Share") was converted into the right to receive $85.00 per Share, net to the seller in cash (the "Offer Price").

F2: The number of Shares reported includes 3,663 unvested restricted Shares (each a "Restricted Share"). Each Restricted Share that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser automatically became fully vested as of immediately prior to, and contingent upon, the effective time of the Merger and was treated in the same manner as an outstanding Share.

F3: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option.

F4: In August 2019, the Reporting Person contributed the Options to a grantor retained annuity trust with his children as beneficiaries.

Sage Therapeutics, Inc.

Report date July 31, 2025 · Filed July 31, 2025

Section 16 reporting ended · disclosed 2025-07-31. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.77 · Expires 2035-06-10	Direct	0	Reported balance After 2025-07-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-07-31 · Disposition to issuer · Disposed 21,500 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer to purchase all outstanding shares of common stock of the Issuer (each, a "Share") for (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes, and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025. F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer to purchase all outstanding shares of common stock of the Issuer (each, a "Share") for (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes, and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time").

F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025.

F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 25, 2026 Filed Sep 29, 2026 11:00 UTC	PRECISION BIOSCIENCES INC DTIL · Entity 6284	PurchaseCommon Stock	2,609	$6.28	$16,384.52	Disclosure SEC source: 0001628280-26-063766 · wk-form4_1790679609.xml · nonDerivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,492 Read SEC document
August 07, 2026 Filed Aug 7, 2026 20:18 UTC	Entera Bio Ltd. ENTX · Entity 5464	GrantStock Option (right to buy) · Derivative	43,014	$0.00 Strike: $1.37	$0.00	Disclosure SEC source: 0001178913-26-003949 · zk2635791.xml · derivative · entry 3 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,014 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 43,014 shares Expires 2036-05-07 F3 · derivative.exercise_date: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest on a quarterly basis over a one-year period that began on February 4, 2026, subject to full acceleration upon a Change in Control (as defined in the Plan). Read SEC document
August 07, 2026 Filed Aug 7, 2026 20:18 UTC	Entera Bio Ltd. ENTX · Entity 5464	GrantStock Option (right to buy) · Derivative	50,000	$0.00 Strike: $1.37	$0.00	Disclosure SEC source: 0001178913-26-003949 · zk2635791.xml · derivative · entry 2 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 50,000 shares Expires 2036-05-07 F2 · derivative.exercise_date: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on February 4, 2026, with one-third of the options vesting on February 4, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan (the "Plan")). Read SEC document
August 07, 2026 Filed Aug 7, 2026 20:18 UTC	Entera Bio Ltd. ENTX · Entity 5464	GrantOrdinary Shares, par value NIS 0.0000769 per share	25,014	$0.00	$0.00	Disclosure SEC source: 0001178913-26-003949 · zk2635791.xml · nonDerivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,014 F1 · kind: The Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Person in lieu of the cash fees the Reporting Person was entitled to for services rendered as a director of the Company for the first quarter and second quarter of 2026. This grant of shares was approved by the Board on August 5, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares, which occurred on August 7, 2026. Read SEC document
June 03, 2026 Filed Jun 5, 2026 11:37 UTC	PRECISION BIOSCIENCES INC DTIL · Entity 6284	GrantRestricted Stock Units · Derivative	20,979	$0.00	$0.00	Disclosure SEC source: 0001628280-26-041041 · wk-form4_1780659437.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,979 Underlying: Common Stock · 20,979 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vest on the earlier to occur of (i) June 3, 2027 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. F2 · derivative.expiration_date: The RSUs vest on the earlier to occur of (i) June 3, 2027 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document
May 20, 2026 Filed May 22, 2026 11:30 UTC	PRECISION BIOSCIENCES INC DTIL · Entity 6284	Exercise / conversionRestricted Stock Units · Derivative	21,000	$0.00	$0.00	Disclosure SEC source: 0001628280-26-037533 · wk-form4_1779449415.xml · derivative · entry 2 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On June 3, 2025 the Reporting person was granted RSUs. The RSUs vested on the earlier to occur of (i) June 3, 2026 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. F3 · derivative.expiration_date: On June 3, 2025 the Reporting person was granted RSUs. The RSUs vested on the earlier to occur of (i) June 3, 2026 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document
May 20, 2026 Filed May 22, 2026 11:30 UTC	PRECISION BIOSCIENCES INC DTIL · Entity 6284	Exercise / conversionCommon Stock	21,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-26-037533 · wk-form4_1779449415.xml · nonDerivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on May 20, 2026. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
May 14, 2026 Filed May 19, 2026 01:51 UTC	Harmony Biosciences Holdings, Inc. HRMY · Entity 4381	GrantStock Option · Derivative	21,231	$0.00 Strike: $30.76	$0.00	Disclosure SEC source: 0001424383-26-000003 · form4-05192026_010535.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,231 Underlying: Common Stock · 21,231 shares Expires 2036-05-14 F1 · derivative.exercise_date: The stock option shall vest in 36 equal monthly installments beginning on June 14, 2026. Read SEC document
March 09, 2026 Filed Mar 11, 2026 12:30 UTC	Entera Bio Ltd. ENTX · Entity 5464	PurchaseOrdinary Shares, par value NIS 0.0000769 per share	20,000	$1.30	$26,000.00	Disclosure SEC source: 0001178913-26-000825 · ownership.xml · nonDerivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Read SEC document
February 10, 2026 Filed Feb 11, 2026 13:45 UTC	Entera Bio Ltd. ENTX · Entity 5464	PurchaseOrdinary Shares, par value NIS 0.0000769 per share	20,000	$1.49	$29,800.00	Disclosure SEC source: 0001178913-26-000413 · ownership.xml · nonDerivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: Not disclosed Read SEC document
December 16, 2025 Filed Dec 17, 2025 12:02 UTC	PRECISION BIOSCIENCES INC DTIL · Entity 6284	PurchaseCommon Stock	3,000	$4.72	$14,160.00	Disclosure SEC source: 0001628280-25-057485 · wk-form4_1765972922.xml · nonDerivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,883 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.718 to $4.720. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote. Read SEC document
July 31, 2025 Filed Jul 31, 2025 15:38 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Disposition to issuerStock Option (Right to Buy) · Derivative	21,500	Not disclosed Strike: $6.77	Not disclosed	Disclosure SEC source: 0000950170-25-100663 · ownership.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,500 shares Expires 2035-06-10 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer to purchase all outstanding shares of common stock of the Issuer (each, a "Share") for (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes, and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). F2 · kind: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof. Read SEC document
June 11, 2025 Filed Jun 13, 2025 20:14 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantStock Option (Right to Buy) · Derivative	21,500	$0.00 Strike: $6.77	$0.00	Disclosure SEC source: 0001562180-25-004794 · primarydocument.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires 2035-06-11 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan in accordance with Sage's Non-Employee Director Compensation Program. The option will vest in full upon the earlier to occur of June 11, 2026 or the day immediately prior to the 2026 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document
June 03, 2025 Filed Jun 4, 2025 21:01 UTC	PRECISION BIOSCIENCES INC DTIL · Entity 6284	GrantRestricted Stock Units · Derivative	21,000	$0.00	$0.00	Disclosure SEC source: 0000950170-25-081728 · ownership.xml · derivative · entry 3 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vest on the earlier to occur of (i) June 3, 2026 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. F4 · derivative.expiration_date: The RSUs vest on the earlier to occur of (i) June 3, 2026 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document
May 27, 2025 Filed Jun 4, 2025 21:01 UTC	PRECISION BIOSCIENCES INC DTIL · Entity 6284	Exercise / conversionRestricted Stock Units · Derivative	9,826	$0.00	$0.00	Disclosure SEC source: 0000950170-25-081728 · ownership.xml · derivative · entry 2 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,826 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On June 4, 2024 the Reporting person was granted RSUs. The RSUs vested on the earlier to occur of (i) June 4, 2025 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. F3 · derivative.expiration_date: On June 4, 2024 the Reporting person was granted RSUs. The RSUs vested on the earlier to occur of (i) June 4, 2025 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document
May 27, 2025 Filed Jun 4, 2025 21:01 UTC	PRECISION BIOSCIENCES INC DTIL · Entity 6284	Exercise / conversionCommon Stock	9,826	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-25-081728 · ownership.xml · nonDerivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of Restricted Stock Units ("RSUs") on May 27, 2025. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
March 25, 2025 Filed Mar 27, 2025 11:00 UTC	PRECISION BIOSCIENCES INC DTIL · Entity 6284	PurchaseCommon Stock	3,250	$5.30	$17,225.00	Disclosure SEC source: 0000950170-25-045720 · ownership.xml · nonDerivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,057 Read SEC document
December 30, 2024 Filed Jan 2, 2025 12:00 UTC	PRECISION BIOSCIENCES INC DTIL · Entity 6284	PurchaseCommon Stock	3,605	$4.49	$16,186.45	Disclosure SEC source: 0000950170-25-000071 · ownership.xml · nonDerivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,807 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.25 to $4.55. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote. Read SEC document
June 10, 2024 Filed Jun 11, 2024 20:58 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $10.90	$0.00	Disclosure SEC source: 0001562180-24-004951 · primarydocument.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-06-09 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan in accordance with Sage's Non-Employee Director Compensation Program. The option will vest in full upon the earlier to occur of June 10, 2025 or the day immediately prior to the 2025 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document
June 04, 2024 Filed Jun 6, 2024 20:37 UTC	PRECISION BIOSCIENCES INC DTIL · Entity 6284	GrantRestricted Stock Units · Derivative	9,826	$0.00	$0.00	Disclosure SEC source: 0000950170-24-069938 · ownership.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,826 Underlying: Common Stock · 9,826 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such shares. F2 · derivative.exercise_date: The RSUs vest on the earlier to occur of (i) June 4, 2025 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. F2 · derivative.expiration_date: The RSUs vest on the earlier to occur of (i) June 4, 2025 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document
May 04, 2024 Filed May 7, 2024 20:25 UTC	PRECISION BIOSCIENCES INC DTIL · Entity 6284	Exercise / conversionRestricted Stock Units · Derivative	4,202	$0.00	$0.00	Disclosure SEC source: 0000950170-24-054581 · ownership.xml · derivative · entry 2 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,202 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On May 4, 2023 the Reporting Person was granted RSUs. The RSUs vested in full on May 4, 2024. F4 · derivative.expiration_date: On May 4, 2023 the Reporting Person was granted RSUs. The RSUs vested in full on May 4, 2024. Read SEC document
May 04, 2024 Filed May 7, 2024 20:25 UTC	PRECISION BIOSCIENCES INC DTIL · Entity 6284	Exercise / conversionCommon Stock	4,202	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-054581 · ownership.xml · nonDerivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,202 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting and settlement of Restricted Stock Units ("RSUs") on May 4, 2024. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3 · balance_after: On February 13, 2024, the Issuer effected a 1-for-30 reverse stock split. The amounts of securities herein have been adjusted to reflect the reverse stock split. Read SEC document
June 15, 2023 Filed Jun 16, 2023 20:06 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $56.10	$0.00	Disclosure SEC source: 0001562180-23-005262 · primarydocument.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-06-15 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 15, 2024 or the day immediately prior to the 2024 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document
May 04, 2023 Filed May 8, 2023 20:15 UTC	PRECISION BIOSCIENCES INC DTIL · Entity 6284	GrantRestricted Stock Units · Derivative	126,075	$0.00	$0.00	Disclosure SEC source: 0001209191-23-027922 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,075 Underlying: Common Stock · 126,075 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such shares. F2 · derivative.exercise_date: The RSUs vest on the earlier to occur of (i) May 4, 2024 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. F2 · derivative.expiration_date: The RSUs vest on the earlier to occur of (i) May 4, 2024 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document
June 16, 2022 Filed Jun 17, 2022 20:35 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantStock Option (Right to Buy) · Derivative	9,947	$0.00 Strike: $31.36	$0.00	Disclosure SEC source: 0001562180-22-005203 · primarydocument.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,947 Underlying: Common Stock · 9,947 shares Expires 2032-06-16 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 16, 2023 or the day immediately prior to the 2023 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document
May 10, 2022 Filed May 12, 2022 11:15 UTC	PRECISION BIOSCIENCES INC DTIL · Entity 6284	GrantStock Option (Right to Buy) · Derivative	156,951	$0.00 Strike: $1.86	$0.00	Disclosure SEC source: 0001209191-22-028449 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,951 Underlying: Common Stock · 156,951 shares Expires 2032-05-09 F1 · derivative.exercise_date: The option vests on the earlier to occur of (i) May 10, 2023 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document
June 10, 2021 Filed Jun 11, 2021 20:09 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $76.09	$0.00	Disclosure SEC source: 0001562180-21-004206 · primarydocument.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-10 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 10, 2022 or the day immediately prior to the 2022 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document
May 10, 2021 Filed May 12, 2021 20:03 UTC	PRECISION BIOSCIENCES INC DTIL · Entity 6284	GrantStock Option (Right to Buy) · Derivative	32,800	$0.00 Strike: $8.07	$0.00	Disclosure SEC source: 0001209191-21-032013 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,800 Underlying: Common Stock · 32,800 shares Expires 2031-05-09 F1 · derivative.exercise_date: The option vests on the earlier of May 10, 2022 or the day immediately prior to the date of the next annual meeting of the Company's stockholders occurring after May 10, 2021, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document
June 09, 2020 Filed Jun 11, 2020 20:18 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $36.47	$0.00	Disclosure SEC source: 0001562180-20-004428 · primarydocument.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-09 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 9, 2021 or the day immediately prior to the 2021 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document
March 10, 2020 Filed Mar 12, 2020 20:36 UTC	PRECISION BIOSCIENCES INC DTIL · Entity 6284	GrantStock Option (Right To Buy) · Derivative	71,776	$0.00 Strike: $7.57	$0.00	Disclosure SEC source: 0001209191-20-018527 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,776 Underlying: Common Stock · 71,776 shares Expires 2030-03-09 F1 · derivative.exercise_date: The option vests over 3 years in 36 substantially equal monthly installments following March 10, 2020. Read SEC document
January 06, 2020 Filed Jan 6, 2020 13:26 UTC	MEDICINES CO /DE MDCO · Entity 152552	Disposition to issuerStock Option · Derivative	8,410	$0.00 Strike: $34.81	$0.00	Disclosure SEC source: 0000950142-20-000043 · es2000128_4-germano.xml · derivative · entry 4 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By grantor retained annuity trust Disclosed balance after: 0 Underlying: Common Stock · 8,410 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option. F4 · ownership.nature: In August 2019, the Reporting Person contributed the Options to a grantor retained annuity trust with his children as beneficiaries. Read SEC document
January 06, 2020 Filed Jan 6, 2020 13:26 UTC	MEDICINES CO /DE MDCO · Entity 152552	Disposition to issuerStock Option · Derivative	9,141	$0.00 Strike: $33.86	$0.00	Disclosure SEC source: 0000950142-20-000043 · es2000128_4-germano.xml · derivative · entry 3 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By grantor retained annuity trust Disclosed balance after: 0 Underlying: Common Stock · 9,141 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option. F4 · ownership.nature: In August 2019, the Reporting Person contributed the Options to a grantor retained annuity trust with his children as beneficiaries. Read SEC document
January 06, 2020 Filed Jan 6, 2020 13:26 UTC	MEDICINES CO /DE MDCO · Entity 152552	Disposition to issuerStock Option · Derivative	27,243	$0.00 Strike: $30.90	$0.00	Disclosure SEC source: 0000950142-20-000043 · es2000128_4-germano.xml · derivative · entry 2 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By grantor retained annuity trust Disclosed balance after: 0 Underlying: Common Stock · 27,243 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option. F4 · ownership.nature: In August 2019, the Reporting Person contributed the Options to a grantor retained annuity trust with his children as beneficiaries. Read SEC document
January 06, 2020 Filed Jan 6, 2020 13:26 UTC	MEDICINES CO /DE MDCO · Entity 152552	Disposition to issuerCommon Stock	7,429	Not disclosed	Not disclosed	Disclosure SEC source: 0000950142-20-000043 · es2000128_4-germano.xml · nonDerivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of November 23, 2019 (the "Merger Agreement"), by and among the Company, Novartis AG ("Parent") and Medusa Merger Corporation ("Purchaser"), on January 6, 2020, Purchaser was merged with and into the Company (the "Merger"), with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each a "Share") was converted into the right to receive $85.00 per Share, net to the seller in cash (the "Offer Price"). F2 · price: The number of Shares reported includes 3,663 unvested restricted Shares (each a "Restricted Share"). Each Restricted Share that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser automatically became fully vested as of immediately prior to, and contingent upon, the effective time of the Merger and was treated in the same manner as an outstanding Share. Read SEC document
June 05, 2019 Filed Jun 6, 2019 20:02 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $177.41	$0.00	Disclosure SEC source: 0001562180-19-003392 · primarydocument.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-05 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 5, 2020 or the day immediately prior to the 2020 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document
May 30, 2019 Filed Jun 3, 2019 17:23 UTC	MEDICINES CO /DE MDCO · Entity 152552	GrantStock Options (right-to-buy) · Derivative	8,410	$0.00 Strike: $34.81	$0.00	Disclosure SEC source: 0001179110-19-007034 · edgar.xml · derivative · entry 2 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,410 Underlying: Common Stock · 8,410 shares Expires 2029-05-30 F2 · derivative.exercise_date: The option vests in one installment on May 30, 2020 and was made as part of and pursuant to the Issuer's director compensation program. Read SEC document
May 30, 2019 Filed Jun 3, 2019 17:23 UTC	MEDICINES CO /DE MDCO · Entity 152552	GrantCommon Stock	3,663	$0.00	$0.00	Disclosure SEC source: 0001179110-19-007034 · edgar.xml · nonDerivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,429 F1 · shares: The restricted stock award vests on May 30, 2020 and was made as part of and pursuant to the Issuer's director compensation program. Read SEC document
January 03, 2019 Filed Jan 4, 2019 21:01 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantStock Option (Right to Buy) · Derivative	878	$0.00 Strike: $89.33	$0.00	Disclosure SEC source: 0001562180-19-000187 · primarydocument.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 878 Underlying: Common Stock · 878 shares Expires 2029-01-03 F1 · derivative.exercise_date: The reporting person elected to receive this stock option award in lieu of payment of all cash retainers that would otherwise be paid for his service during 2019 on the issuer's board or its committees, as permitted under the issuer's amended and restated non-employee director compensation policy. The stock option is granted under and subject to the terms of the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. The option will vest in full on December 31, 2019, subject to the reporting person's continued service through such date. Read SEC document
June 06, 2018 Filed Jun 8, 2018 20:03 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $154.06	$0.00	Disclosure SEC source: 0001562180-18-002928 · primarydocument.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-06 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2014 Stock Option and Incentive Plan. The option will vest in full upon the earlier to occur of June 6, 2019 or the day immediately prior to the 2019 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document
May 31, 2018 Filed Jun 4, 2018 16:52 UTC	MEDICINES CO /DE MDCO · Entity 152552	GrantStock Option (right-to-buy) · Derivative	9,141	$0.00 Strike: $33.86	$0.00	Disclosure SEC source: 0001179110-18-007955 · edgar.xml · derivative · entry 2 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,141 Underlying: Common Stock · 9,141 shares Expires 2028-05-31 F2 · derivative.exercise_date: The option vests in one installment on May 31, 2019 and was made as part of and pursuant to the Issuer's director compensation program. Read SEC document
May 31, 2018 Filed Jun 4, 2018 16:52 UTC	MEDICINES CO /DE MDCO · Entity 152552	GrantCommon Stock	3,766	$0.00	$0.00	Disclosure SEC source: 0001179110-18-007955 · edgar.xml · nonDerivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,766 F1 · shares: The restricted stock award vests on May 31, 2019 and was made as part of and pursuant to the Issuer's director compensation program. Read SEC document
March 08, 2018 Filed Mar 8, 2018 17:27 UTC	Bioverativ Inc. BIVV · Entity 168487	Disposition to issuerNon-Qualified Stock Option · Derivative	21,729	Not disclosed Strike: $55.04	Not disclosed	Disclosure SEC source: 0001127602-18-010662 · form4.xml · derivative · entry 2 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,729 shares Expires not disclosed F4 · shares: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F4 · price: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. Read SEC document
March 08, 2018 Filed Mar 8, 2018 17:27 UTC	Bioverativ Inc. BIVV · Entity 168487	Disposition to issuerRestricted Stock Units · Derivative	5,455	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-18-010662 · form4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,455 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock. F2 · shares: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3 · shares: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F3 · price: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. Read SEC document
January 31, 2018 Filed Feb 2, 2018 22:14 UTC	Bioverativ Inc. BIVV · Entity 168487	GrantRestricted Stock Units · Derivative	5,455	$0.00	$0.00	Disclosure SEC source: 0001127602-18-003809 · form4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,455 Underlying: Common Stock · 5,455 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in full on the first anniversary of the date of grant. F2 · derivative.expiration_date: The restricted stock units vest in full on the first anniversary of the date of grant. Read SEC document
November 09, 2017 Filed Nov 20, 2017 17:24 UTC	MEDICINES CO /DE MDCO · Entity 152552	GrantCall Option (right-to-buy) · Derivative	27,243	$0.00 Strike: $30.90	$0.00	Disclosure SEC source: 0001179110-17-014381 · edgar.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,243 Underlying: Common Stock · 27,243 shares Expires 2027-11-09 F1 · derivative.exercise_date: This option vests in one installment on November 9, 2020 and is made part of and pursuant to Issuer's director compensation package. Read SEC document
June 07, 2017 Filed Jun 8, 2017 23:38 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantStock Option (Right to Buy) · Derivative	14,000	$0.00 Strike: $72.74	$0.00	Disclosure SEC source: 0001562180-17-002239 · primarydocument.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2027-06-07 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2014 Stock Option and Incentive Plan. The option will vest in full upon the earlier to occur of June 7, 2018 or the day immediately prior to the 2018 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document
May 11, 2017 Filed May 15, 2017 21:02 UTC	Bioverativ Inc. BIVV · Entity 168487	GrantNon-Qualified Stock Option · Derivative	21,729	$0.00 Strike: $55.04	$0.00	Disclosure SEC source: 0001127602-17-018094 · form4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,729 Underlying: Common Stock · 21,729 shares Expires 2027-05-11 F1 · derivative.exercise_date: This option vests in three equal annual installments beginning on May 11, 2018. Read SEC document
September 22, 2016 Filed Sep 26, 2016 22:29 UTC	PRECIGEN, INC. XON · Entity 4356	GrantOption to Purchase Common Stock (Right to Buy) · Derivative	1,000,000	$0.00 Strike: $29.94	$0.00	Disclosure SEC source: 0001225385-16-000081 · edgar.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2026-05-31 F1 · shares: This award represents the Issuer's remaining obligation to grant the reporting person option awards for 2,000,000 shares. A Form 4 dated June 3, 2016 reported that the reporting person previously received an option for 2,000,000 shares. That Form 4 has subsequently been amended to reflect that the initial grant was only effective with respect to 1,000,000 shares. This Form 4 reports that the reporting person has now received an option for the remaining 1,000,000 shares. F2 · derivative.exercise_date: These options vest in 25% increments on June 1, 2017, 2018, 2019 and 2020. Read SEC document
June 01, 2016 Filed Sep 26, 2016 22:28 UTC Amendment	PRECIGEN, INC. XON · Entity 4356	GrantOption to Purchase Common Stock (Right to Buy) · Derivative	1,000,000	$0.00 Strike: $29.94	$0.00	Disclosure SEC source: 0001225385-16-000080 · edgar.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2026-06-01 F1 · shares: The original Form 4 filed on June 3, 2016 previously reported a grant of an option for 2,000,000 shares in connection with the reporting person's appointment as President of the Issuer. However, the option grant was only effective with respect to 1,000,000 shares, and this report is being filed to correct the prior over-reporting of the grant. On September 22, 2016, the reporting person was granted an option with respect to the remaining 1,000,000 option shares to which he was entitled. Those options are being reported on a separate Form 4. F2 · derivative.exercise_date: These options vest in 25% increments on June 1, 2017, 2018, 2019 and 2020. Read SEC document
February 26, 2015 Filed Feb 27, 2015 23:27 UTC	PFIZER INC PFE · Entity 2863	GrantStock Appreciation Rights · Derivative	120,805	$0.00 Strike: $34.59	$0.00	Disclosure SEC source: 0001225208-15-006196 · doc4.xml · derivative · entry 10 Germano Geno J · CIK 0001424383 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,805 Underlying: Common Stock · 120,805 shares Expires 2022-02-26 F9 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F9 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.